On the risk of delisting of ordinary shares of Oncternal Therapeutics, Inc. (ONCT)

The International Trading System Limited (hereinafter — ITS) informs of the delisting risk in respect of ordinary shares of Oncternal Therapeutics, Inc. (ISIN US68236P2065, hereinafter — Shares, QI) from The NASDAQ Stock Market LLC (hereinafter — Nasdaq).

Information on delisting risk of ordinary shares by Nasdaq

On November 25, 2024, Oncternal Therapeutics, Inc. (hereinafter — the Company) submitted a report on Form 8-K to The United States Securities and Exchange Commission. According to the report, on November 22, 2024 the Company received a notice from Nasdaq indicating that, based on the Company’s announcement on November 14, 2024 of a workforce reduction of all of its remaining employees and exploration of strategic alternatives, Nasdaq believes the Company is a “public shell” and will suspend trading of the Shares before the open of business on December 3, 2024 and commence proceedings to delist the Shares.

Information regarding possible actions to be taken by ITS Ltd.

 ITS conducts regular monitoring of the relevant information disclosed by the Company. Delisting of the Shares by Nasdaq will be considered to constitute a breach of the ITS Regulations on admitting financial instruments to trading and result in termination of trading in the QI on ITS. A separate notice will be published by ITS  outlining how trading in these qualified investments will be restricted on ITS before its termination.